Gruenenthal, Depomed deal

Gruenenthal will grant Depomed exclusive rights to develop and commercialize cebranopadol in the U.S. and Canada. The small molecule opioid analgesic is in Phase II testing for moderate to severe pain. Gruenenthal will receive a $25 million upfront payment and will be eligible for undisclosed sales milestones and double-digit royalties. The deal is expected to close this quarter. ...